New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...
Tony Wood, GSK’s chief scientific officer, said: “We are excited by this new data which shows that a single dose of Arexvy ...
RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
RSV vaccination was associated with decreased risks for infection and hospitalization, although the decrease was not statistically significant.
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Viking ...
Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi ...
In this live event, Centers for Disease Control and Prevention Director Mandy Cohen shares the latest information about respiratory illnesses for this fall and winter, and answer questions about ...